Model 03
A defined assay protocol, agreed readouts and a written technical report. Recommended for antioxidant, antiproliferative and antimicrobial screening. You receive data you can act on immediately, not a promise of future experiments.
How we work
The pathway is designed to de-risk your decision in the cheapest possible order. A free call establishes whether there is a fit. A feasibility scan tests the assumptions on paper before any lab time is booked. An NDA is signed before you disclose anything sensitive. Only then do we quote a pilot. If the science holds, we move to a commercial structure.
Model 01 · Start here
A focused 30-minute conversation about your pipeline, the compound or protein of interest, the application and IP considerations. No commitment. We establish together whether there is a fit and what the right next step is.
Model 02
Before lab time is allocated, we assess your target, application and intended use scientifically and technically. The fastest way to test assumptions — and far cheaper than a pilot that runs in the wrong direction.
Model 04
An 8–12 week R&D engagement with defined milestones, mechanistic data and a full deliverable package including a technical report and recommendations. For companies that need a complete scientific narrative, not just a screen result.
Model 05
A multi-month engagement: protein engineering campaigns, enzyme directed evolution, lead compound validation and mechanism-of-action studies. Regular reporting, and IP discussed from the outset. For pipeline investments that need academic-grade rigour.
Model 06
For partners where the science has proven itself and now needs a commercial structure: NDA, data room, licence terms, milestone payments, royalty models or a joint development agreement. We are open to all structures.
A free 30-minute call establishes whether there is a fit and what the right next step is. Every inquiry is acknowledged within one working day and answered by the responsible group leader within three.
